Higher expression of a 121-gene T-lymphocyte signature was demonstrated to correlate with longer survival, especially among rituximab-treated T-DLBCL patients, and high expression of individual T-lymphocyte surface markers such as CD3D/E/G, CD4, and CD8A/B was shown to translate to favorable outcomes, emphasizing the prognostic impact of TILs [23]. The gene discussed is CD4; the disease is diffuse large B-cell lymphoma.